Literature DB >> 11449204

Effects of intranasal corticosteroids on the hypothalamic-pituitary-adrenal axis in children.

A L Boner1.   

Abstract

In adults, morning plasma cortisol levels are twice that of late afternoon and evening values. In children, a delay in the time of onset in peak cortisol levels has been observed in those treated with inhaled corticosteroids. Consequently, the single morning cortisol level has a low sensitivity for detecting adrenal insufficiency in children. It is not clear which test is best for detection of clinically relevant hypothalamic-pituitary-adrenal (HPA) axis suppression in children; 24-hour plasma cortisol is a good test because it measures biologically active, free cortisol levels for the entire day and is noninvasive. For research purposes, the 24-hour integrated concentration plasma cortisol test is preferred. Studies that have looked at HPA axis suppression with intranasal corticosteroids indicate that overall, intranasal corticosteroids have minimal effect on the HPA axis. A review of the literature reveals one study in which there was a decreased output of urinary cortisol during treatment with either budesonide or fluticasone propionate in adults. Other studies of fluticasone propionate or budesonide have shown no effect on the HPA axis in children. Beclomethasone dipropionate was shown to affect urinary cortisol output in one study of healthy volunteers. However, in a long-term study in children, no effect on the HPA axis was found. Mometasone furoate has been extensively studied in more than 20 trials of adults and children. No effects on the HPA axis were detected in either children or adults. It is unlikely that children are more sensitive to corticosteroids than are adults. There seems to be little point in performing routine monitoring of adrenal function in children who are treated with intranasal corticosteroid treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11449204     DOI: 10.1067/mai.2001.115564

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  8 in total

Review 1.  Safety of intranasal corticosteroid sprays during pregnancy: an updated review.

Authors:  Ahmed H Alhussien; Riyadh A Alhedaithy; Saad A Alsaleh
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-21       Impact factor: 2.503

2.  Systemic activity of inhaled corticosteroid treatment in asthmatic children: corticotrophin releasing hormone test.

Authors:  L Pescollderungg; G Radetti; E Gottardi; D G Peroni; A Pietrobelli; A L Boner
Journal:  Thorax       Date:  2003-03       Impact factor: 9.139

3.  Nasal steroid perspective: knowledge and attitudes.

Authors:  Cemal Cingi; Murat Songu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-11-21       Impact factor: 2.503

4.  Role of intranasal topical steroid in pediatric sleep disordered breathing and influence of allergy, sinusitis, and obesity on treatment outcome.

Authors:  Yong Gi Jung; Hyo Yeol Kim; Jin-Young Min; Hun-Jong Dhong; Seung-Kyu Chung
Journal:  Clin Exp Otorhinolaryngol       Date:  2011-03-17       Impact factor: 3.372

5.  Combination of mometasone furoate and oxymetazoline for the treatment of adenoid hypertrophy concomitant with allergic rhinitis: A randomized controlled trial.

Authors:  Wenlong Liu; Lifeng Zhou; Qingxiang Zeng; Renzhong Luo
Journal:  Sci Rep       Date:  2017-01-18       Impact factor: 4.379

Review 6.  Chinese expert recommendation on transnasal corticosteroid nebulization for the treatment of chronic rhinosinusitis 2021.

Authors:  Chengshuo Wang; Lei Cheng; Huabin Li; Zheng Liu; Hongfei Lou; Jianbo Shi; Ying Sun; Dehui Wang; Qintai Yang; Hongmeng Yu; Changqing Zhao; Dongdong Zhu; Fengli Cheng; Yan Li; Bo Liao; Meiping Lu; Cuida Meng; Shen Shen; Yueqi Sun; Rui Zheng; Luo Zhang
Journal:  J Thorac Dis       Date:  2021-11       Impact factor: 2.895

7.  Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center.

Authors:  Corine Rollema; Eric N van Roon; Corine Ekhart; Florence P A M van Hunsel; Tjalling W de Vries
Journal:  Drugs Real World Outcomes       Date:  2022-06-03

8.  Randomised, crossover clinical trial, in healthy volunteers, to compare the systemic availability of two topical intranasal budesonide formulations.

Authors:  Jaime Algorta; Maria Angeles Pena; Silvia Francisco; Zurine Abajo; Emilio Sanz
Journal:  Trials       Date:  2008-06-09       Impact factor: 2.279

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.